𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cell-mediated and humoral immunity studies of murine and hamster sarcoma virus-induced producer and non-producer tumors in syngeneic animals

✍ Scribed by James L. McCoy; Robert C. Ting; Nancy T. McCoy; Joel I. Reisher; Sue P. Chan; Lloyd W. Law

Publisher
John Wiley and Sons
Year
1974
Tongue
French
Weight
774 KB
Volume
13
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Murine sarcoma virus (MSV)‐induced transformed tumor cells, which are releasers and non‐releasers of virus, were investigated by transplantation immunity and a variety of serological assays. Transplantation immunity demonstrated that tumor‐associated transplantation antigens could be detected on producer cells and were also apparent, but to a lesser degree, on non‐releaser cells of BALB/c mouse origin. Some lymphocyte microcytotoxicity tests employing hamster MSV tumors failed to detect any in vitro immunity. Studies employing immunofluorescence, complement fixation and virus focus neutralization tests demonstrated that Harvey‐MSV producer cells of hamster origin were strongly immunogenic in inducing antibody formation in syngeneic hamsters. By contrast, no antibody could usually be detected by these techniques following immunization with non‐producer Harvey‐MSV or immunization with either Moloney‐MSV non‐producer cells or those non‐producer cells that had been made releasers by treatment with IUDR in syngeneic hosts. The results suggest that humoral antibody, as detected by the techniques employed, is probably produced largely in response to infectious MSV contained by producer tumor cells and is not directed against new cell neoantigens, whereas transplantation immunity is probably, in part, a response to non‐virion neoantigens.

📜 SIMILAR VOLUMES

Cell-surface antigens of murine sarcoma-
Cell-surface antigens of murine sarcoma-virus-transformed non-producer cells: Further evidence for lack of transplantation immunity
✍ Joel S. Greenberger; John R. Stephenson; Tadao Aoki; Stuart A. Aaronson 📂 Article 📅 1974 🏛 John Wiley and Sons 🌐 French ⚖ 629 KB

## Abstract Previous studies have indicated that cells transformed by murine sarcoma virus (MSV) in the absence of virus production lack detectable transplantation antigens. Recent findings that antibodies to a surface antigen associated with MSV‐transformed cells can be elicited by hyperimmunizati

Rescue of the genome of the defective mu
Rescue of the genome of the defective murine sarcoma virus from a non-producer hamster tumor cell line, pm-1, with murine and feline leukemia viruses as helpers
✍ C. Monti-Bragadin; K. Ulrich 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 French ⚖ 691 KB

## Abstract Some properties of a hamster tumor cell line, the PM‐1 cl 6 (PM‐1), derived from a hamster tumor induced by the Harvey murine sarcoma virus (H‐MuSV) are described. The PM‐1 cell line appears to be free of viruses of the murine leukemia‐sarcoma complex as tested by the absence of plaque

Cell-mediated reaction against tumors in
Cell-mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in Murine sarcoma virus (MSV)-induced tumors and transplanted lymphomas
✍ J. C. Leclerc; E. Gomard; J. P. Levy 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 French ⚖ 781 KB

## Abstract Anti‐tumour cell‐mediated immune reactions were studied by the chromium release test (CRT) in mice bearing autochtonous Murine Sarcoma Virus (MSV)‐induced sarcomas or syngeneic transplants of lymphomas with various antigenic specificities. Cytotoxic lymphoid cells were detected during t

Cell-mediated immunity to Moloney sarcom
Cell-mediated immunity to Moloney sarcoma virus in mice. II. Analysis of antigenic specificities involved in T lymphocyte-mediated in vivo rejection of murine sarcoma virus-induced tumors
✍ R. M. Gorczynski; R. A. Knight 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 814 KB

## Abstract Sublethally irradiated BALB/c mice innoculated with Moloney sarcoma virus (MSV‐M) develop progressively growing tumors and die within 30 days of virus innoculation. These animals can be protected from tumor progression (and death) by innoculation of small numbers of MSV‐immune T lymphoc

Expression of IL-27 in murine carcinoma
Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals
✍ Masako Chiyo; Osamu Shimozato; Ling Yu; Kiyoko Kawamura; Toshihiko Iizasa; Takeh 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 176 KB

## Abstract A novel cytokine interleukin‐27 (IL‐27), composed of p28 and Epstein‐Barr virus‐induced gene 3 (EBI3), is produced from activated dendritic cells and is involved in an early phase of T‐helper type I differentiation. We examined whether Colon 26 murine colon carcinoma cells that were ret

Cell-mediated and humoral immune respons
Cell-mediated and humoral immune responses to tumor-associated and viral antigens in relation to the pathogenic effect of rous sarcoma virus in rats
✍ Nils Jonsson 📂 Article 📅 1971 🏛 John Wiley and Sons 🌐 French ⚖ 660 KB

## Abstract After inoculation of the Schmidt‐Ruppin strain of Rous sarcoma virus (SR‐RSV) into a series of newborn rats (strain R/F) sarcomas developed in 47% of the animals, half of which also had hemorrhagic‐cystic lesions. In 18% such hemorrhagic cysts occurred without demonstrable tumors, while